Clinical trialNACompleted
Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer
Phase I Trial of Adaptive Stereotactic Body Radiotherapy (SBRT) Dose Escalation in Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- 20 June 2014
- Expected end
- 31 December 2022
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- Maximum Tolerated Dose
- Sponsor
- Other
- Results posted
- 2025-09-12
- Last update
- 12 September 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is to determine the maximum tolerated dose (MTD) of five fraction stereotactic radiotherapy (SBRT) in pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
This trial is designed to find the maximum tolerated dose of radiation under a fixed 5-fraction SBRT regimen escalating the dose from 40 Gy in 5 fractions, to 60 Gy in 5 fractions, at 5 Gy intervals.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Maximum Tolerated Dose [From date of randomization to observed dose limiting toxicity (DLT) in 20% of patients assessed up to 3 years]. Number, Gray. All Participants (n=30): 50.